Fundación Lucha contra el Sida

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients

Transdermal rivastigmine for HIV-associated cognitive impairment: A randomized pilot study

Variable endothelial cell function restoration after initiation of two antiretroviral regimens in HIV-infected individuals

Use of a physiologically based pharmacokinetic model to simulate drug–drug interactions between antineoplastic and antiretroviral drugs

Time to get serious with HIV-1 resistance in sub-Saharan Africa

Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy.

Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals